Skip to main content

Remote Job Finders (RJF)

Longevity Biotechs Strive for Better Aging—Not Just Life Extension

The industry sector focused on aging is only about 10 years old, but acting on what scientists already know, a new crop of biotechs, backed by investors, are taking a disease-centric approach to extending the human lifespan.

Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the “litigation risk is back on the table” now that the Danish pharma has stepped away.

Concentra Snags Another Struggling Biotech as Cargo Accepts $200M Buyout

The deal marks an end for CAR T company Cargo Therapeutics, which has been slashing its workforce and cutting programs since the January decision to halt its lead candidate for a certain type of aggressive large B cell lymphoma.

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Viehbacher spied a possible deal, but the smaller company wasn’t interested.

California Manufacturing Jobs Dip But Still Key to State as Investment Continues

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, several companies made—and continuing making—significant manufacturing investments in the state as key trends shape the discipline.
Scroll to top